| Outcome Measures: |
Primary: Change in VAT/(VAT+SAT) from baseline to 12 months, Measured as VAT/Subcutaneous Adipose Tissue + VAT changes over 1 year., baseline and 12 months|Change in hepatic insulin resistance from baseline to 12 months, Hepatic insulin resistance, measured by serum concentration of beta-hydroxybutyrate (surrogate marker of acetyl-CoA, which regulates gluconeogenesis), changes over 1 year., baseline and 12 months|Change in triglycerides from baseline to 12 months, Change in triglycerides after a high-fat mixed meal tolerance test, expressed as the total Area Under the Curve (AUCTG) over 6 hours from baseline to 1 year., baseline and 12 months | Secondary: Change in weight from baseline to 12 months, Mean change in weight (kilograms) assessed using a scale, baseline and 12 months|Change in percent body fat from baseline to 12 months, Mean change in percent body fat assessed using DEXA scan measurements, baseline and 12 months|Change in BMI from baseline to 12 months, Mean change in BMI calculated using measured height and weight., baseline and 12 months|Change in mean glucose concentration, Change in mean glucose concentration. Data collected as available using participant's personal clinical continuous glucose monitor., baseline and 12 months|Mean time in normal glucose range, Mean time in normal glucose range. Range=70-180 mg/dl and 3.9-10 mmol/L. Data collected as available using participant's personal clinical continuous glucose monitor., baseline and 12 months|Mean time in level 1 and 2 hyperglycemia, high range, Mean time in level 1 and 2 hyperglycemia. Range= \>180, \>250 mg/dL and \>10, \>13.9 mmol/L. Data collected as available using participant's personal clinical continuous glucose monitor., baseline and 12 months|Mean time in level 1 and 2 hyperglycemia, low range, Mean time in level 1 and 2 hyperglycemia. Range= \<70, \<54 mg/dL and \<3.9, \<3.0 mmol/L. Data collected as available using participant's personal clinical continuous glucose monitor., baseline and 12 months
|
